Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustainable metallic biomaterials for orthopaedic implants: a comprehensive review of biodegradable and conventional metals.

Biomedical materials (Bristol, England)·2026
Same author

Towards trustworthy brain stroke diagnosis using a lightweight explainable deep learning framework for CT imaging.

Scientific reports·2026
Same author

A Metal Importer and Exporter Interact Differently in the Chloroplast and Cell Membrane.

Membranes·2026
Same author

Smartphone interfaced image based creatinine estimation on a novel micro pipette tip-based platform: Whole blood sample-to-creatinine readout.

Analytica chimica acta·2026
Same author

Development of Bioisosteres of Iboga Alkaloids: A Step-Economical Synthesis to Enhance the Antinociceptive and Anxiolytic Activity with Neuroprotective Effects.

ACS pharmacology & translational science·2026
Same author

Homology Modeling and Pharmacophore Based Inhibitor Design Targeting Isocitrate Lyase of Madurella mycetomatis-A Novel Approach Against Eumycetoma.

Chemistry & biodiversity·2026
Same journal

Artificial Intelligence in the Prehospital Stage of Stroke: Can Virtual Assistants Optimize Triage?

The neurologist·2026
Same journal

Looking Beyond the Midline: An Uncommon Etiology of Internuclear Ophthalmoplegia of Abduction Due to Cerebral Venous Thrombosis.

The neurologist·2026
Same journal

Commentary: Cervical Artery Dissection and Chiropractic Cervical Manipulation: Clarifying Association, Mechanism, and Interpretation.

The neurologist·2026
Same journal

Acute Spinal Cord Infarct Secondary to Fibrocartilaginous Embolism Treated With Tenecteplase.

The neurologist·2026
Same journal

Cervical Artery Dissection and Chiropractic​​​​​.

The neurologist·2026
Same journal

Oromandibular Dyskinesia Associated With Levofloxacin and Responsive to Low-Dose Oral Diazepam: A Case Report.

The neurologist·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 27, 2013

Safety and Effectiveness of Routine Tenecteplase Use in a Large Telestroke Network.

Arpan Dutta1, Arnab Sarkar2, Subhadeep Gupta1

  • 1Department of Neurology, Institute of Postgraduate Medical Education and Research, Kolkata, India.

The Neurologist
|March 3, 2026
PubMed
Summary
This summary is machine-generated.

Tenecteplase is a safe and effective alternative to Alteplase for acute ischemic stroke (AIS) management. This study found no significant differences in outcomes, hemorrhage, or mortality between Tenecteplase and Alteplase in a large telestroke network.

Keywords:
alteplaseischemic stroketenecteplasethrombolysis

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
06:38

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

Related Experiment Videos

Last Updated: May 10, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 27, 2013

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
06:38

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Tenecteplase is an emerging thrombolytic agent for acute ischemic stroke (AIS).
  • Evidence suggests Tenecteplase is non-inferior to Alteplase in AIS management.
  • Tenecteplase offers advantages in cost, administration, and recanalization for large vessel occlusions.

Purpose of the Study:

  • To evaluate the safety and effectiveness of routine Tenecteplase use in a large Indian telestroke network.
  • To compare Tenecteplase with Alteplase in terms of patient outcomes and safety profiles.
  • To assess real-world data on Tenecteplase utilization in AIS management.

Main Methods:

  • Retrospective observational study of AIS patients from the Swasthya Ingit Telestroke Program in West Bengal, India (January 2022 - December 2024).
  • Comparison of patients receiving Tenecteplase versus Alteplase for thrombolysis.
  • Primary outcome measures included good functional outcome (modified Rankin Scale 0-2 at 90 days), symptomatic intracranial hemorrhage, and 3-month all-cause mortality.

Main Results:

  • 1526 patients were analyzed; 1389 received Tenecteplase and 137 received Alteplase.
  • No significant association was found between Tenecteplase use and favorable outcomes (OR: 1.03, P=0.93).
  • Tenecteplase use was not associated with increased symptomatic intracranial hemorrhage (OR: 0.63, P=0.41) or all-cause mortality (OR: 0.54, P=0.15).

Conclusions:

  • Routine Tenecteplase administration for acute ischemic stroke is safe and effective in real-world clinical practice.
  • The study supports Tenecteplase as a viable alternative to Alteplase in telestroke networks.
  • Real-world data confirms the non-inferiority and safety of Tenecteplase in AIS management.